Mantle Cell Lymphoma (MCL) Part One: Treatment Advances

Benjamin Lampson, MD, PhD

Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.

Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.

CLICK HERE to participate in our episode survey.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Eli Lilly & Company.


  1. I had an auto stem cell transplant last August – they tested me for covid antibodies after that and I actually had antibodies! I am being treated at Dartmouth Hitchcock with Eric Jacobsen, MD at Dana Farber consulting.

  2. The LLS presentation on MCL was outstanding in the clarity and description of the disease and the latest treatment options. This was the first time that I have truly understood the origin of MCL and how it affects the body. I’ve had this now for five years and had all the classic symptoms and am now on Zanubrutinib with good results after a rocky start with Ibrutinib.
    It would be interesting to know if a follow=up study is being done for Covid antibodies over time and the possibilities of a 5th dose in the near future??
    Thanks again

    1. Hi Axel,

      Thank you for listening! Regarding your question about the antibody study. This is an ongoing study and LLS is starting to gather data around the 4th and now 5th doses. Keep an eye on for new updates. Moderately and severely immunocompromised patients are eligible for 5th doses at 4 months post the 4th dose. The updated dosing schedule is here. You can also listen to our recent podcast about vaccines and antibodies with the primary investigators of the LLS study at

  3. Thank you Dr. Lampson and LLS for a very informative and encouraging Podcast on MCL. A job well done!

  4. Thank you for making this podcast about MCL. I have been in remission from Stage 4 MCL since 2015 but I’m closely following treatment developments and the research into the disease’s characteristics. I’m also a donor to LLS.

Leave a Comment

Your email address will not be published. Required fields are marked *